HCA Healthcare (2BH) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2BH Analyst Ratings

Moderate Buy

11 Buy

7 Hold

1 Sell

Based on 19 analysts giving stock ratings to

HCA

Healthcare

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2BH Stock 12 Month Forecast

Average Price Target

€391.55

▲(13.69% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for HCA Healthcare in the last 3 months. The average price target is €391.55 with a high forecast of €502.06 and a low forecast of €329.50. The average price target represents a 13.69% change from the last price of €344.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"305":"€305","404":"€404","503":"€503","354.5":"€354.5","453.5":"€453.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":502.05678264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€502.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":391.5484100266666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€391.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":329.5018608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€329.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[305,354.5,404,453.5,503],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.3,357.35821404923075,369.41642809846155,381.4746421476923,393.5328561969231,405.59107024615383,417.64928429538463,429.7074983446154,441.7657123938462,453.8239264430769,465.8821404923077,477.94035454153845,489.9985685907692,{"y":502.05678264,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.3,348.85757000205126,352.41514000410257,355.9727100061538,359.5302800082051,363.0878500102564,366.6454200123077,370.20299001435893,373.76056001641024,377.3181300184615,380.8757000205128,384.43327002256405,387.9908400246153,{"y":391.5484100266666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.3,344.0847585230769,342.8695170461539,341.6542755692308,340.4390340923077,339.22379261538464,338.00855113846154,336.79330966153844,335.57806818461535,334.3628267076923,333.1475852307692,331.9323437538461,330.7171022769231,{"y":329.5018608,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":306.917,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.986,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":359.702,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":394.727,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":429.453,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":399.005,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":409.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.319,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.182,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.362,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.955,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":345.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€502.06

Average Price Target€391.55

Lowest Price Target€329.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Baxter

Wells Fargo

€319.96→€330.37

Hold

-4.07%

Downside

Assigned

08/03/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (NYSE: ATR), Myriad Genetics (NASDAQ: MYGN) and HCA Healthcare (NYSE: HCA)

Ann Hynes

Mizuho Securities

€455.23→€411.88

Buy

19.59%

Upside

Reiterated

07/28/26

HCA Healthcare price target lowered to $475 from $525 at MizuhoHCA Healthcare price target lowered to $475 from $525 at Mizuho

Brian Tanquilut

Jefferies

€390.2

Buy

13.30%

Upside

Reiterated

07/28/26

Jefferies Remains a Buy on HCA Healthcare (HCA)

Lance Wilkes

Bernstein

€369.39

Hold

7.26%

Upside

Reiterated

07/28/26

Bernstein Keeps Their Hold Rating on HCA Healthcare (HCA)

David S Macdonald

Truist Financial

€463.9→€429.22

Buy

24.63%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and HCA Healthcare (NYSE: HCA)

Michael Wiederhorn

Oppenheimer

€450.9→€420.55

Buy

22.11%

Upside

Reiterated

07/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

A.J. Rice

UBS

€550.61→€502.06

Buy

45.78%

Upside

Reiterated

07/27/26

HCA Healthcare price target lowered to $579 from $635 at UBSHCA Healthcare price target lowered to $579 from $635 at UBS

Pito Chickering

Deutsche Bank

€468.24→€412.74

Buy

19.84%

Upside

Assigned

07/27/26

HCA Healthcare price target lowered to $476 from $540 at Deutsche BankHCA Healthcare price target lowered to $476 from $540 at Deutsche Bank

Scott Fidel

Goldman Sachs

€483.85→€420.55

Buy

22.11%

Upside

Assigned

07/27/26

HCA Healthcare price target lowered to $485 from $558 at Goldman SachsHCA Healthcare price target lowered to $485 from $558 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

€368.52→€329.5

Sell

-4.33%

Downside

Reiterated

07/27/26

HCA Healthcare price target lowered to $380 from $425 at Morgan StanleyHCA Healthcare price target lowered to $380 from $425 at Morgan Stanley

Matthew Gillmor CFA

KeyBanc

€411.88→€377.19

Buy

9.52%

Upside

Reiterated

07/27/26

Analysts Conflicted on These Healthcare Names: HCA Healthcare (NYSE: HCA), Summit Therapeutics (NASDAQ: SMMT) and Neuphoria Therapeutics (NASDAQ: NEUP)

Ryan Langston

TD Cowen

€373.72

Buy

8.51%

Upside

Assigned

07/27/26

HCA Healthcare: Buy Rating Reiterated as Margin Stability and Cost Discipline Support Upside, Price Target Maintained at $431

Michael Ha

Robert W. Baird

€343.38→€340.77

Hold

-1.05%

Downside

Reiterated

07/27/26

HCA Healthcare price target lowered to $393 from $396 at BairdHCA Healthcare price target lowered to $393 from $396 at Baird

Ben Hendrix

RBC Capital

€377.19

Buy

9.52%

Upside

Reiterated

07/26/26

RBC Capital Remains a Buy on HCA Healthcare (HCA)

Andrew Mok CFA

Barclays

€348.58→€335.57

Hold

-2.56%

Downside

Reiterated

07/26/26

HCA Healthcare price target lowered to $387 from $402 at BarclaysHCA Healthcare price target lowered to $387 from $402 at Barclays

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Baxter

Wells Fargo

€319.96→€330.37

Hold

-4.07%

Downside

Assigned

08/03/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (NYSE: ATR), Myriad Genetics (NASDAQ: MYGN) and HCA Healthcare (NYSE: HCA)

Ann Hynes

Mizuho Securities

€455.23→€411.88

Buy

19.59%

Upside

Reiterated

07/28/26

HCA Healthcare price target lowered to $475 from $525 at MizuhoHCA Healthcare price target lowered to $475 from $525 at Mizuho

Brian Tanquilut

Jefferies

€390.2

Buy

13.30%

Upside

Reiterated

07/28/26

Jefferies Remains a Buy on HCA Healthcare (HCA)

Lance Wilkes

Bernstein

€369.39

Hold

7.26%

Upside

Reiterated

07/28/26

Bernstein Keeps Their Hold Rating on HCA Healthcare (HCA)

David S Macdonald

Truist Financial

€463.9→€429.22

Buy

24.63%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and HCA Healthcare (NYSE: HCA)

Michael Wiederhorn

Oppenheimer

€450.9→€420.55

Buy

22.11%

Upside

Reiterated

07/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

A.J. Rice

UBS

€550.61→€502.06

Buy

45.78%

Upside

Reiterated

07/27/26

HCA Healthcare price target lowered to $579 from $635 at UBSHCA Healthcare price target lowered to $579 from $635 at UBS

Pito Chickering

Deutsche Bank

€468.24→€412.74

Buy

19.84%

Upside

Assigned

07/27/26

HCA Healthcare price target lowered to $476 from $540 at Deutsche BankHCA Healthcare price target lowered to $476 from $540 at Deutsche Bank

Scott Fidel

Goldman Sachs

€483.85→€420.55

Buy

22.11%

Upside

Assigned

07/27/26

HCA Healthcare price target lowered to $485 from $558 at Goldman SachsHCA Healthcare price target lowered to $485 from $558 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

€368.52→€329.5

Sell

-4.33%

Downside

Reiterated

07/27/26

HCA Healthcare price target lowered to $380 from $425 at Morgan StanleyHCA Healthcare price target lowered to $380 from $425 at Morgan Stanley

Matthew Gillmor CFA

KeyBanc

€411.88→€377.19

Buy

9.52%

Upside

Reiterated

07/27/26

Analysts Conflicted on These Healthcare Names: HCA Healthcare (NYSE: HCA), Summit Therapeutics (NASDAQ: SMMT) and Neuphoria Therapeutics (NASDAQ: NEUP)

Ryan Langston

TD Cowen

€373.72

Buy

8.51%

Upside

Assigned

07/27/26

HCA Healthcare: Buy Rating Reiterated as Margin Stability and Cost Discipline Support Upside, Price Target Maintained at $431

Michael Ha

Robert W. Baird

€343.38→€340.77

Hold

-1.05%

Downside

Reiterated

07/27/26

HCA Healthcare price target lowered to $393 from $396 at BairdHCA Healthcare price target lowered to $393 from $396 at Baird

Ben Hendrix

RBC Capital

€377.19

Buy

9.52%

Upside

Reiterated

07/26/26

RBC Capital Remains a Buy on HCA Healthcare (HCA)

Andrew Mok CFA

Barclays

€348.58→€335.57

Hold

-2.56%

Downside

Reiterated

07/26/26

HCA Healthcare price target lowered to $387 from $402 at BarclaysHCA Healthcare price target lowered to $387 from $402 at Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering HCA Healthcare

3 Months

Michael WiederhornOppenheimer

Success Rate

25/37 ratings generated profit

Average Return

+6.73%

Copying Michael Wiederhorn's trades and holding each position for 3 Months would result in 67.57% of your transactions generating a profit, with an average return of +6.73% per trade.

1 Year

Scott FidelGoldman Sachs

Success Rate

25/28 ratings generated profit

Average Return

+18.20%

Copying Scott Fidel's trades and holding each position for 1 Year would result in 89.29% of your transactions generating a profit, with an average return of +18.20% per trade.

2 Years

Whit MayoLeerink Partners

Success Rate

44/46 ratings generated profit

Average Return

+50.63%

Copying Whit Mayo's trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +50.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2BH Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2BH has received 24 Buy Ratings, 14 Hold Ratings, and 2 Sell Ratings. 2BH average Analyst price target in the past 3 months is 391.55.

Each month's total comprises the sum of three months' worth of ratings.

2BH Financial Forecast

2BH Earnings Forecast

Next quarter’s earnings estimate for 2BH is €5.89 with a range of €5.06 to €6.47. The previous quarter’s EPS was €6.59. 2BH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.94% of the time in the same period. In the last calendar year 2BH has Performed in-line its overall industry.

2BH Sales Forecast

Next quarter’s sales forecast for 2BH is €16.85B with a range of €16.33B to €17.34B. The previous quarter’s sales results were €17.57B. 2BH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.47% of the time in the same period. In the last calendar year 2BH has Performed in-line its overall industry.

2BH Stock Forecast FAQ

What is DE:2BH’s average 12-month price target, according to analysts?

Based on analyst ratings, Hca Healthcare’s 12-month average price target is 391.55.

What is DE:2BH’s upside potential, based on the analysts’ average price target?

Hca Healthcare has 13.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hca Healthcare a Buy, Sell or Hold?

Hca Healthcare has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 7 hold ratings and 1 sell ratings.

What is Hca Healthcare’s share price target?

The average share price target for Hca Healthcare is 391.55. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €502.06 ,and the lowest forecast is €329.50. The average share price target represents 13.69% Increase from the current price of €344.4.

What do analysts say about Hca Healthcare?

Hca Healthcare’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Hca Healthcare?

To buy shares of DE:2BH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

HCA Healthcare (2BH) Stock Forecast & Price Target

2BH Analyst Ratings

2BH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering HCA Healthcare

2BH Analyst Recommendation Trends

2BH Financial Forecast

2BH Earnings Forecast

2BH Sales Forecast

2BH Stock Forecast FAQ

Detailed List of Analyst Forecasts